* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Pharmacology Ch 9 110-126 Cholinergic Pharmacology
Survey
Document related concepts
Discovery and development of beta-blockers wikipedia , lookup
CCR5 receptor antagonist wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
Toxicodynamics wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
NMDA receptor wikipedia , lookup
Psychopharmacology wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Transcript
Pharmacology Ch 9 110-126 Cholinergic Pharmacology Acetylcholine is involved in neuromuscular junction (NMJ), ANS, and CNS -Cholinergic receptors are divided into two classes: 1. Muscarinic Cholinergic Receptors – G protein linked receptors on ALL parasympathetic postganglionic fibers (few sympathetic), and in CNS 2. Nicotinic Cholinergic Receptors – ligand-gated ion channels at excitatory autonomic synapses and in CNS presynpatics -Acetylcholinesterase (AChE) – enzyme that degrades acetylcholine Synthesis of Acetylcholine – synthesized in 1 step from coline + Acetyl CoA by choline acetyltransferase (ChAT) -50% of choline generated by acetylcholinasterase in synaptic cleft is transported back into axon terminal where it comprises 50% of choline used in ACh synthesis -choline is stored in phospholipids as phosphorylcholine -acetyl-coA is generated mainly from glycolysis and is produced by pyruvate dehydrogenase -rate limiting step of ACh synthesis is mediated by availability of choline, which depends on uptake of choline into the neuron -choline is taken into the neuron through facilitated diffusion and a Na-dependent transporter found in cholinergic nerve terminals Storage and Release of ACh – ACh transported into synaptic vesicles for storage after synthesis -an ATPase pumping protons into vesicle provides energy for process; then (protons out = ACh in) through ACh-H antiport channel -antiport channel is a target of vesamicol, acts to cause deficit of ACh storage and release -cholinergic vesicles also contain ATP and heparan sulfate proteoglycans which serve as counter ions to neutralize the positive charge of ACh and disperse electrostatic forces that prevent dense packing of ACh within vesicle -Release of ACh occurs through fusion of synaptic vesicle with membrane; dependent on opening of voltage-dependent Ca channels -increase in intracellular Ca facilitates binding of synpatotagmin to SNARE complex to mediate attachment of fusion of vesicle and release of transmitters into synaptic cleft -Two stores of ACh play distrinct roles in process of release 1. depot pool – vesicles positioned near plasma membrane of axon terminal; axonal depolarization cause vesicles to release ACh rapidly 2. reserve pool – refill the depot pool as it is being used Muscarinic Receptors – mainly at autonomic ganglia, at end organs innervated by parasympathetics, and in CNS; they are GTP binding G proteins; several mechanisms: 1. Inhibition of adenylyl cyclase via Gi and stimulation of phospholipase C mediated by alpha subunit 2. Also influences ion channels via second messenger molecules; predominantly increases opening of specific potassium (K) channels to hyperpolarize the cells mediated by beta/gamma subunits of the G protein -5 different muscarinic receptors exist labeled M1-5 (M1,3,5 stimulate phospholipase C, M2,4 open K channels to hyperpolarize cell) -M1 is expressed in cortical neurons/autonomic ganglia, M2 in cardiac muscle, M3 in smooth muscle and glandular tissue -M1, 3, 5 EXCITE Cell -M2, 4 INHIBIT Cell Nicotinic Receptors – causes direct ligand-gated conductance. Two ACh molecules bind to one receptor to elicit a conformational change to create monovalent cation-selective pore that is equally permeable to Na and K ions (Na is predominant due to Nernst potential) -these can depolarize the cell immediately -ACh rapidly dissociates from receptor and is degraded by AChE so stimulation is brief -structure in NMJ is α2βεδ form, while in embryo it is α2βγδ -besides opening and closing, nicotinic receptors also modulate responses to concentrations of ACh -continuous ACh stimulation causes desensitization of receptor in which it is closed -nicotinic receptors at autonomic ganglia and CNS are termed (N2 or NN) are similar to the ones at NMJ (N1 or NM) Degradation of Acetylcholine – cholinesterases degrade acetylcholine; type types of cholinesterases are AChE and butyrylcholinesterase (BuChE); BuChE plays a secondary role in ACh degradation and can play a role in early neural development as coregulator of ACh Neuromuscular Junction – ACh is neurotransmitter at neuromuscular junction; binding of ACh released by alpha motor neurons to nicotinic receptors in muscle cell membrane results in motor end-plate depolarization -extent of depolarization depends on quantity of ACh released into synaptic cleft -each quantum of ACh is a single synaptic vesicle and elicits a small depolarization in motor endplate termed miniature end-plate potential (MEPP) -large depolarization of end-plate is called end-plate potential (EPP) triggers AP in muscle fiber -ACh depolarizes muscle AND modulates its own action at this site -presynaptic cholinergic receptors on axon terminal of motor neuron respond to ACh binding by FACILITATING mobilization of synaptic vesicles from reserve pool to the depot pool -only when 50% or more of postsynaptic receptors are desensitized is decline in muscle tension observed during tetanic stimulation (known as tetanic fade) -blockade of moldulatory presynaptic cholinergic receptors by antagonists such as hexamethonium prevents facilitation and causes rapid tetanic fade to occur Autonomic Effects – primary event in postsynaptic ganglionic response is rapid depolarization mediated by nicotinic ACh receptors on postganglionic neuron similar to that of NMJ in that inward current elicits immediate EPSP; 3 other events remaining that modulate primary signal: -known as slow EPSP, IPSP, and late/slow EPSP Slow EPSP – occurs after a latency of 1s and is mediated by M1 muscarinic ACh receptors IPSP – product of catecholamine (dopamine and norepinephrine) stimulation of dopaminergic and alpha-adrenergic receptors, but some by M2 muscarinic receptors) Late/Slow EPSP – mediated by decrease in K conductance induced by stimulation of receptors for peptide transmitters, angiotensin, substance P, LHRH; plays a role in long-term regulation of postsynaptic neuron sensitivity to repetitive stimulation -drugs against slow EPSP, IPSP, and late/slow IPSP cannot eliminate ganglionic transmission, but instead only alter efficiency of transmission; methacholine, a muscarinic receptor agonist, resembles stimulation of slow EPSPs -overall effect of ganglionic blockade is complex and depends on relative predominance of sympathetic and parasympathetic tone at various end organs -heart influenced primarily by parasympathetic system whose tonic effect is a slowing of heart rate, so blockade of autonomic ganglia that innervates the heart by moderate to high doses of atropine results in blockade of vagal slowing of SA node tachycardia -blood vessels influenced by sympathetic system; and sympathetic stimulation causes vasoconstriction. Ganglionic blockade results in VASODILATION CNS Effects – CNS functions of ACh include modulation of sleep, wakefulness, learning, memory, suppression of pain at spinal cord, neural plasticity, early neural development, immunosuppression, and epilepsy -as part of the ascending reticular activating system – cholinergic neurons play a role in arousal and attention and levels of ACh in brain INCREASE during wakefulness and REM and decrease during inattentive states and non-REM/slow-wave sleep -acetylcholine potentiates excitatory effects of other inputs to its cortical target cells without affecting the baseline activity of neurons; modulates excitatory neurotransmitter release -during awake states, ACh prevents interference in hippocampus during initial learning by suppressing retrieval of stored memories, but release of this suppression is necessary to allow consolidation of new memories -acetylcholine plays a role in pain modulation through inhibition of spinal nociception Pharmacologic Agents and Drugs – there are many variations of cholinergic drugs used for various diseases. -pirenzepine binds M1 receptor (autonomic ganglia) with higher affinity than M2 and M3 -Methacholine – more resistant to degradation by AChE and possesses longer duration of action -Physostigmine – agent of choice for treating CNS effects of anticholinergic overdose; penetrates CNS well Inhibitors of Acetylcholine Synthesis, Storage, and Release 1. Hemicholinium-3 blocks high affinity transporter for choline and prevents uptake of choline for ACh synthesis 2. Vesamicol – blocks ACh-H antiporter used to transport ACh into vesicles to prevent storage 3. Botulinum Toxin A – degrades SNAP-25 and prevents vesicle fusion to axon terminal, used to treat torticollis, achalasia, strabismus, and others Acetylcholinesterase Inhibitors – agents bind and inhibit AChE to elevate concentration of ACh -all indirect cholinergic agonists interfere AChE by binding to active site of enzyme; three different classes (alcohols, carbamic acid esters, and organic phosphoric acid derivatives); pharmacokinetic differences 1. Edrophonium – simple alcohol inhibits AChE by reservible association on active site, short acting and ideal for diagnostic purposes; helpful in diagnosing competitive AChR antagonists or myasthenia gravis/Eaton-Lambert Syndrome 2. Neostigmine – carbamic ester blocks AChE but also activates nicotinic AChRs at NMJ (irreversible) 3. Physostigmine – carbamic ester that is fairly irreversible -all of these increase increase transmission at NMJ, increase parasympathetic tone, and increase central cholinergic activity (treats alzheimers disease); TREATS MYASTHENIA GRAVIS -AChE inhibitors cannot reverse agents that cause paralysis by inducing sustained depolarization -for chronic myasthenia gravis, use longer-acting AChEs such as pyridostigmine, neostigmine, and ambenonium -CNS AChE inhibitors can cause GI symtoms like nausea, vomiting, anorexia, flatulence, diarrhea; use drug after a meal Receptor Agonists – cholinergic receptor agonists bind to ACh binding site of cholinergic receptors; can be divided into muscarinic/nicotinic-selective agents -muscarinic receptor agonists are used clinically in asthma diagnosis and miotics (pupil constrict) -nicotinic receptor agonists are used for induction of muscle paralysis 1. Choline Esters: Methacholine – 3x more resistant to hydrolysis by AChE than ACh and is selective for cardiovascular muscarinic receptors; little affinity for nicotinic receptors -use limited for vasodilation (vagomimetic) -diagnosis of asthma (causes exaggerated bronchoconstriction) Carbachol – resistant to AChE and has enhanced nicotinic actions, used as a topical miotic agent in treatment of glaucoma to cause pupillary constriction and decreased intraocular pressure Bethanechol – selective for muscarinic receptors, promoting GI and urinary motility 2. Alkaloids: Muscarine – low bioavailability because it is charged Pilocarpine – miotic agent and a sialagogue (saliva-inducing agent) used to trat xerosotomia Cevimeline – M1 and M3 agonist treats xerostomia in Sjogren’s syndrome Nicotinic Receptor Agonists Succinylcholine – high affinity for nicotinic receptors and is resistant to AChE, used to induce paralysis during surgery by causing depolarizing blockade; can lead to electrolyte imbalance -pattern is period of excitation, widespread fasciculations in muscle cells, followed by paralysis -any nAChR agonist is capable of producing depolarizing blockade Receptor Antagonists – act by binding directly to agonist site and blocking stimulation Muscarinic Receptor Antagonists – 1. Atropine – induces mydriasis (pupil dilation), to reverse symptomatic sinus bradycardia, inhibit excessive salivation and mucus secretion, and counteract muscarinic poisoning 2. Scopolamine – has CNS effects and treats motion sickness, antiemetic, transdermal patch exists; can ameliorate nausea 3. Methscopolamine and Glycopyrrolate – low CNS penetration used to decrease oral secretions, treat peptic ulcer disease, decrease GI spasms, and prevent bradycardia (glycopyrrolate) 4. Pirenzepine – selective for M1 and M4 receptors is an alternative to H2 receptor antagonists 5. Ipratropium – more effective than B adrenergic agonists in treatment of COPD but less effective at treating asthma 6. Tiotropium – bronchodilates and treats COPD -antimuscarinics promote detrusor relaxation and tightening of bladder sphincter; treatment for overactive bladder are :oxybutynin, propantheline, terodiline, tolterodine, fesoterodine, trospium, darifenacin, and solifenacin to treat Parkinson’s disease, people use amantadine, benztropine, procyclidine, and trihexyphenidyl -benztropine and trihexyphenidyl also treats symptoms and akathisia associated with neuroleptics -antimuscarinic toxicity causes substantial morbidity in geriatric population by causing bradycardia and sedation -over the counter drug diphenhydramine is an antihistamine and anticholinergic drug that can cause morbidity in people older than 65 Nicotinic Receptor Antagonists – produce nondepolarizing (competitive) neuromuscular blockage during surgical procedures Tubocurare antagonizes ACh receptor directly to prevent ACh binding and depolarization -duration of action is important: d-tubocurarine, pancuronium are LONG LASTING vecuronium and rocuronium are INTERMEDIATE DURATION mivacurium is RAPIDLY DEGRADED